Krystal Biotech, Inc. (KRYS)
Health Care ยท Biological Products, (No Diagnostic Substances)
Krystal Biotech, Inc. (KRYS) is listed on Nasdaq, where its shares have traded since September 20, 2017. SentiSense covers Krystal Biotech, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Krish S. Krishnan is its chief executive officer. The company reports 295 employees, and its corporate website is www.krystalbio.com.
About Krystal Biotech, Inc.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Latest reported results
Krystal Biotech, Inc. reported revenue of $127.3 million for Q3 FY2026, up 30.2% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 411 institutions reported holding KRYS, with 30.3 million shares worth $11.1 billion in aggregate. The largest reported holders were FMR, BlackRock and Vanguard. Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter.
More on KRYS
- KRYS sentiment: whether news and social coverage of Krystal Biotech, Inc. leans bullish or bearish, and the stories driving it.
- KRYS ownership: all 411 reporting institutions, plus insider and congressional trades.
- KRYS financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
Frequently asked questions
What does Krystal Biotech, Inc. do?
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs.
What sector is KRYS in?
SentiSense classifies Krystal Biotech, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does KRYS stock trade?
Krystal Biotech, Inc. (KRYS) is listed on Nasdaq, where its shares have traded since September 20, 2017.
Who is the CEO of Krystal Biotech, Inc.?
Krish S. Krishnan is the chief executive officer of Krystal Biotech, Inc..